Barclays initiated coverage of Lumexa Imaging (LMRI) with an Overweight rating and $23 price target The firm likes the company’s strong local market positions and accelerating new center openings. Lumexa benefits from rising demand for diagnostic imaging due to increasing chronic diseases and the shift to lower-cost care sites,the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMRI:
- Lumexa Imaging initiated with a Buy at Deutsche Bank
- Lumexa Imaging Holdings: Secular Tailwinds, High-Return Expansion, and Joint-Venture Model Support Buy Rating
- Lumexa Imaging initiated with an Outperform at Leerink
- Lumexa Imaging initiated with an Outperform at Raymond James
- Lumexa Imaging initiated with an Outperform at William Blair